Financials data is unavailable for this security.
View more
Year on year ReShape Lifesciences Inc had revenues fall -22.79% from 11.24m to 8.68m, though the company grew net income from a loss of 46.21m to a smaller loss of 11.39m.
Gross margin | 67.47% |
---|---|
Net profit margin | -112.11% |
Operating margin | -119.44% |
Return on assets | -98.88% |
---|---|
Return on equity | -184.59% |
Return on investment | -169.55% |
More ▼
Cash flow in USDView more
In 2023, ReShape Lifesciences Inc increased its cash reserves by 15.27%, or 604.00k. Cash Flow from Financing totalled 17.57m or 202.51% of revenues. In addition the company used 16.96m for operations while cash used for investing totalled 10.00k.
Cash flow per share | -0.5302 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.1033 |
---|---|
Tangible book value per share | 0.1033 |
More ▼
Balance sheet in USDView more
Current ratio | 1.90 |
---|---|
Quick ratio | 0.8875 |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼